Mesoblast Limited (ASX: MSB) experienced a significant pullback today, ending a four-month rally and making it the worst-performing stock in the ASX200. The decline prompts questions about the sustainability of the company’s recent gains.
The biotech firm’s shares closed 6.16% lower today, reversing some of the gains made during a period where the stock had more than doubled from its 52-week low of A$1.26 to close at A$2.59. While the year-to-date return remains negative at -16.45%, the one-year performance shows a substantial 71.52% increase, highlighting the stock’s volatile nature.
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - Invest in ASX and international shares - Read our review
Mesoblast has seen significant stock price volatility over the past year. A key event was the FDA approval of Ryoncil® (remestemcel-L) in May for pediatric steroid-refractory acute graft versus host disease (SR-aGVHD).
This approval led to a surge in the stock price and positive market sentiment, further amplified by the successful commercial launch highlighted at global healthcare conferences. Inclusion in the Nasdaq Biotechnology Index in December 2024 also boosted the company’s visibility and market confidence.
Additionally, the FDA’s Rare Pediatric Disease designation for Revascor, aimed at treating hypoplastic left heart syndrome (HLHS), provided potential priority review vouchers, accelerating the drug’s development and approval process and leading to a significant rise in share price. In January, Mesoblast announced a proposed issue of 10,228,239 ordinary fully paid securities, a move intended to strengthen the company’s financial position and support its product pipeline.
However, the company has also faced setbacks. In August 2023, the FDA issued a Complete Response Letter (CRL) regarding its Biologics License Application (BLA) for remestemcel-L, requesting additional data, which led to a significant drop in Mesoblast’s share price. While plans to resubmit the BLA for remestemcel-L in March 2024 spurred a substantial increase in the company’s stock price, analyst downgrades in December 2024 contributed to a 5.7% decline, reflecting concerns over the company’s financial performance and product pipeline challenges.
The markets will be closely watching Mesoblast’s progress with the resubmitted BLA for remestemcel-L and the commercial performance of Ryoncil. The company’s ability to navigate regulatory hurdles and achieve commercial success will be crucial in determining its future stock performance.
Don’t Buy Just Yet
You will want to see this before you make any decisions.
Before you decide which shares to add to your portfolio you might want to take a look at this special report we recently published.
Our experts picked out The 5 best ASX shares to buy in 2025.
We’re giving away this valuable research for FREE.
Click below to secure your copy
